Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to thymidine phosphorylase mutations

I Nishino, A Spinazzola, A Papadimitriou… - Annals of Neurology …, 2000 - Wiley Online Library
I Nishino, A Spinazzola, A Papadimitriou, S Hammans, I Steiner, CD Hahn, AM Connolly…
Annals of Neurology: Official Journal of the American Neurological …, 2000Wiley Online Library
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive
disorder defined clinically by severe gastrointestinal dysmotility; cachexia; ptosis,
ophthalmoparesis, or both; peripheral neuropathy; leukoencephalopathy; and mitochondrial
abnormalities. The disease is caused by mutations in the thymidine phosphorylase (TP)
gene. TP protein catalyzes phosphorolysis of thymidine to thymine and deoxyribose 1‐
phosphate. We identified 21 probands (35 patients) who fulfilled our clinical criteria for …
Abstract
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disorder defined clinically by severe gastrointestinal dysmotility; cachexia; ptosis, ophthalmoparesis, or both; peripheral neuropathy; leukoencephalopathy; and mitochondrial abnormalities. The disease is caused by mutations in the thymidine phosphorylase (TP) gene. TP protein catalyzes phosphorolysis of thymidine to thymine and deoxyribose 1‐phosphate. We identified 21 probands (35 patients) who fulfilled our clinical criteria for MNGIE. MNGIE has clinically homogeneous features but varies in age at onset and rate of progression. Gastrointestinal dysmotility is the most prominent manifestation, with recurrent diarrhea, borborygmi, and intestinal pseudo‐obstruction. Patients usually die in early adulthood (mean, 37.6 years; range, 26–58 years). Cerebral leukodystrophy is characteristic. Mitochondrial DNA (mtDNA) has depletion, multiple deletions, or both. We have identified 16 TP mutations. Homozygous or compound heterozygous mutations were present in all patients tested. Leukocyte TP activity was reduced drastically in all patients tested, 0.009 ± 0.021 μmol/hr/mg (mean ± SD; n = 16), compared with controls, 0.67 ± 0.21 μmol/hr/mg (n = 19). MNGIE is a recognizable clinical syndrome caused by mutations in thymidine phosphorylase. Severe reduction of TP activity in leukocytes is diagnostic. Altered mitochondrial nucleoside and nucleotide pools may impair mtDNA replication, repair, or both. Ann Neurol 2000;47:792–800
Wiley Online Library